JP2003525912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003525912A5 JP2003525912A5 JP2001564801A JP2001564801A JP2003525912A5 JP 2003525912 A5 JP2003525912 A5 JP 2003525912A5 JP 2001564801 A JP2001564801 A JP 2001564801A JP 2001564801 A JP2001564801 A JP 2001564801A JP 2003525912 A5 JP2003525912 A5 JP 2003525912A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- polymer
- preparation according
- nucleic acid
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 description 19
- 238000009472 formulation Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 125000000129 anionic group Chemical group 0.000 description 12
- 229920002643 polyglutamic acid Polymers 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 229920006318 anionic polymer Polymers 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 229920000805 Polyaspartic acid Polymers 0.000 description 5
- 108010020346 Polyglutamic Acid Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 108010064470 polyaspartate Proteins 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 229920002230 Pectic acid Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 229960002989 glutamic acid Drugs 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000010318 polygalacturonic acid Substances 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 229920006317 cationic polymer Polymers 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 159000000000 sodium salts Chemical group 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical group [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18723600P | 2000-03-03 | 2000-03-03 | |
| US60/187,236 | 2000-03-03 | ||
| US26175101P | 2001-01-16 | 2001-01-16 | |
| US60/261,751 | 2001-01-16 | ||
| PCT/US2001/006953 WO2001066149A2 (en) | 2000-03-03 | 2001-03-02 | Nucleic acid formulations for gene delivery and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003525912A JP2003525912A (ja) | 2003-09-02 |
| JP2003525912A5 true JP2003525912A5 (enExample) | 2008-04-17 |
| JP4987205B2 JP4987205B2 (ja) | 2012-07-25 |
Family
ID=26882847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001564801A Expired - Lifetime JP4987205B2 (ja) | 2000-03-03 | 2001-03-02 | 遺伝子送達用核酸製剤および使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7173116B2 (enExample) |
| EP (1) | EP1259265B1 (enExample) |
| JP (1) | JP4987205B2 (enExample) |
| AT (1) | ATE511400T1 (enExample) |
| AU (1) | AU2001245427A1 (enExample) |
| BR (1) | BR0108962A (enExample) |
| CA (1) | CA2401327C (enExample) |
| DK (1) | DK1259265T3 (enExample) |
| WO (1) | WO2001066149A2 (enExample) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040192593A1 (en) * | 1999-07-26 | 2004-09-30 | Baylor College Of Medicine | Protease resistant ti-growth hormone releasing hormone |
| KR20020047096A (ko) * | 1999-07-26 | 2002-06-21 | 크로커 사무엘 에스 | 초활성 돼지 성장 호르몬 분비 호르몬 유사체 |
| CA2423093C (en) | 2000-09-25 | 2013-09-17 | Valentis, Inc. | Improved system for regulation of transgene expression |
| US7338656B2 (en) | 2001-10-26 | 2008-03-04 | Baylor College Of Medicine | Composition and method to alter lean body mass and bone properties in a subject |
| WO2003059382A2 (en) * | 2001-12-28 | 2003-07-24 | Supratek Pharma Inc. | Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression |
| US20080269153A1 (en) * | 2002-05-28 | 2008-10-30 | Ruxandra Draghia-Akli | Increased stability of a dna formulation by including poly-l-glutamate |
| US20040014645A1 (en) * | 2002-05-28 | 2004-01-22 | Advisys, Inc. | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
| WO2003099341A1 (en) * | 2002-05-28 | 2003-12-04 | Advisys, Inc. | Increased delivery of a nucleic acid constrtuct in vivo by the poly-l-glutamate (plg) system |
| DE60336736D1 (de) * | 2002-07-16 | 2011-05-26 | VGX Pharmaceuticals LLC | Codon-optimierte synthetische plasmide |
| AU2003302337A1 (en) * | 2002-12-31 | 2004-07-29 | The Johns Hopkins University | Wound healing method and kits |
| CA2513743C (en) * | 2003-01-28 | 2013-06-25 | Advisys, Inc. | Reducing culling in herd animals growth hormone releasing hormone (ghrh) |
| ES2309508T3 (es) * | 2003-03-11 | 2008-12-16 | Laboratoires Serono Sa | Vectores de expresion que comprenden el promotor de mcmv-ie2. |
| AU2004229465B2 (en) * | 2003-04-09 | 2010-04-29 | The United States Of America Department Of Veterans Affairs | Compositions and methods related to production of erythropoietin |
| TW200424214A (en) * | 2003-04-21 | 2004-11-16 | Advisys Inc | Plasmid mediated GHRH supplementation for renal failures |
| GB0313916D0 (en) * | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| US20090005333A1 (en) * | 2004-01-26 | 2009-01-01 | Vgx Pharmaceuticlas, Inc. | Reducing culling in herd animals growth hormone releasing hormone (ghrh) |
| DK2438931T3 (da) | 2004-09-22 | 2013-12-02 | St Jude Childrens Res Hospital | Forbedret ekspression af faktor ix i genterapivektorer |
| TWI294460B (en) * | 2004-12-23 | 2008-03-11 | Ind Tech Res Inst | Method for stabilizing nucleic acids |
| US20060094023A1 (en) * | 2004-11-02 | 2006-05-04 | Industrial Technology Research Institute | Method for isolating nucleic acid by using amino surfactants |
| JP2009518044A (ja) * | 2005-12-07 | 2009-05-07 | ジェネトロニクス，インコーポレイティド | 可変容積エレクトロポレーションチャンバー及びその使用方法 |
| KR101529448B1 (ko) | 2006-03-03 | 2015-06-18 | 온코섹 메디컬 인코포레이티드 | 외과적 절제술 이후에 조직내 남아 있는 미세 잔류 종양을 치료하는 장치 |
| DK2094086T3 (da) * | 2006-11-08 | 2013-11-25 | Veritas Bio LLC | Indgivelse in vivo af dobbeltstrenget rna til en målcelle |
| FR2941152B1 (fr) * | 2009-01-20 | 2013-10-18 | Centre Nat Rech Scient | Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques. |
| WO2012018594A2 (en) * | 2010-07-26 | 2012-02-09 | Scott & White Healthcare | Plant-derived polysaccharides for delivery of rna-based therapies |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| EP2741785B1 (en) | 2011-07-12 | 2018-09-05 | Philadelphia Health and Education Corporation | Novel clostridium difficile dna vaccine |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| SG11201400527XA (en) | 2011-09-16 | 2014-04-28 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer |
| US9708384B2 (en) | 2011-09-22 | 2017-07-18 | The Trustees Of The University Of Pennsylvania | Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens |
| HRP20220250T1 (hr) | 2011-10-03 | 2022-04-29 | Modernatx, Inc. | Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe |
| WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| SI2791160T1 (sl) | 2011-12-16 | 2022-07-29 | Modernatx, Inc. | Sestave modificirane MRNA |
| SG11201404284SA (en) | 2012-02-22 | 2014-10-30 | Univ Pennsylvania | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
| CA3205751A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| JP2015524255A (ja) | 2012-07-13 | 2015-08-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法 |
| US9365641B2 (en) | 2012-10-01 | 2016-06-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| HUE058785T2 (hu) | 2012-10-08 | 2022-09-28 | Biontech Delivery Tech Gmbh | Karboxilált poliamin-származékok, mint transzfekciós reagensek |
| SMT202200337T1 (it) | 2012-11-26 | 2022-09-14 | Modernatx Inc | Rna modificato al livello del terminale |
| PL2956477T5 (pl) | 2013-02-15 | 2024-05-27 | Bioverativ Therapeutics Inc. | Zoptymalizowany gen czynnika viii |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA2931547A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
| ES2963718T3 (es) | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
| JP7372728B2 (ja) | 2014-10-31 | 2023-11-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改変ｔ細胞に関する方法および組成物 |
| AU2015339743C1 (en) | 2014-10-31 | 2021-04-22 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified T cells and uses thereof |
| CN107106609A (zh) | 2014-10-31 | 2017-08-29 | 宾夕法尼亚大学董事会 | 刺激和扩展t细胞的组合物和方法 |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| CA2975147C (en) | 2015-01-31 | 2025-06-10 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS OF ADMINISTRATION OF THERAPEUTIC MOLECULES TO T CELLS |
| HK1250569A1 (zh) | 2015-05-01 | 2018-12-28 | The Regents Of The University Of California | 聚醣依赖性免疫治疗分子 |
| EP3340998B1 (en) | 2015-08-28 | 2023-01-11 | The Trustees of the University of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| PT3411478T (pt) | 2016-02-01 | 2022-09-13 | Bioverativ Therapeutics Inc | Genes do fator viii otimizados |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| US10233419B2 (en) | 2016-06-30 | 2019-03-19 | Zymergen Inc. | Apparatuses and methods for electroporation |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| CA3058425A1 (en) | 2017-03-28 | 2018-10-04 | The Trustees Of The University Of Pennsylvania | Methods to protect transplanted tissue from rejection |
| EP3684399A1 (en) | 2017-12-29 | 2020-07-29 | Cellectis | Method for improving production of car t cells |
| CN118325839A (zh) | 2018-03-27 | 2024-07-12 | 宾夕法尼亚大学董事会 | 具有增强功能的修饰的免疫细胞及其筛选方法 |
| AU2019269601A1 (en) | 2018-05-17 | 2020-11-26 | Regents Of The University Of Minnesota | Drug-resistant immune cells and methods of use thereof |
| US12497611B2 (en) | 2018-08-17 | 2025-12-16 | Yale University | Compositions and methods for high-throughput activation screening to boost T cell effector function |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| US20220170097A1 (en) | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
| WO2020191102A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
| CN120944827A (zh) | 2019-03-27 | 2025-11-14 | 宾夕法尼亚大学董事会 | Tn-MUC1嵌合抗原受体(CAR)T细胞疗法 |
| WO2021067389A1 (en) | 2019-09-30 | 2021-04-08 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| US20220387626A1 (en) | 2019-10-23 | 2022-12-08 | Yale University | Compositions and methods comprising viral vector systems for multiplexed activation of endogenous genes as immunotherapy and viral-based immune-gene therapy |
| WO2021178896A1 (en) | 2020-03-06 | 2021-09-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| AU2021244937A1 (en) | 2020-03-27 | 2022-11-03 | Mendus B.V. | In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CA3172449A1 (en) | 2020-03-27 | 2021-09-30 | Erik Hans MANTING | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| US12173307B2 (en) | 2020-06-24 | 2024-12-24 | Bioverativ Therapeutics Inc. | Methods for the purification of viral vectors |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| EP4210832A1 (en) | 2020-09-14 | 2023-07-19 | Vor Biopharma, Inc. | Chimeric antigen receptors for treatment of cancer |
| CA3196677A1 (en) | 2020-11-05 | 2022-05-12 | Erik Hans MANTING | Use of tumor-independent antigens in immunotherapies |
| CA3203705A1 (en) | 2021-01-22 | 2022-07-28 | Erik Hans MANTING | Methods of tumor vaccination |
| US20250326855A1 (en) | 2021-03-05 | 2025-10-23 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| KR20240107093A (ko) | 2021-08-05 | 2024-07-08 | 고 테라퓨틱스, 인크. | 항-글리코-muc4 항체 및 그의 용도 |
| TW202328188A (zh) | 2021-09-03 | 2023-07-16 | 美商Ｇｏ治療公司 | 抗醣化-cmet抗體及其用途 |
| AU2022339819A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| US20240002800A1 (en) | 2022-05-16 | 2024-01-04 | Mendus B.V. | Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy |
| WO2024236547A1 (en) | 2023-05-18 | 2024-11-21 | Inceptor Bio, Llc | Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof |
| WO2025046513A1 (en) | 2023-08-29 | 2025-03-06 | Inceptor Bio, Llc | Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof |
| CN119925619A (zh) * | 2024-12-31 | 2025-05-06 | 首都医科大学 | 一种递送外源质粒dna的赋形剂及其制备和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4543252A (en) * | 1982-01-21 | 1985-09-24 | The Regents Of The University Of California | Cationic oligopeptides having microbicidal activity |
| ATE26584T1 (de) * | 1983-07-01 | 1987-05-15 | Battelle Memorial Institute | In-vivo abbaubares polypeptid und dessen anwendung zur verzoegerten freigabe von medikamenten. |
| ATE60340T1 (de) * | 1984-10-19 | 1991-02-15 | Battelle Memorial Institute | Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten. |
| US5749847A (en) * | 1988-01-21 | 1998-05-12 | Massachusetts Institute Of Technology | Delivery of nucleotides into organisms by electroporation |
| JP3368603B2 (ja) * | 1992-02-28 | 2003-01-20 | オリンパス光学工業株式会社 | 遺伝子治療用処置具 |
| US5439440A (en) * | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
| WO1994024983A2 (en) | 1993-04-28 | 1994-11-10 | Ribozyme Pharmaceuticals, Inc. | Ocular delivery of nucleic acid |
| US5679647A (en) * | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| FR2715847B1 (fr) * | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| US6271205B1 (en) * | 1994-09-21 | 2001-08-07 | University Of Massachusetts Medical Center | Cancer treatment by expression of differentiation factor receptor |
| US6040295A (en) * | 1995-01-13 | 2000-03-21 | Genemedicine, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
| FR2732218B1 (fr) * | 1995-03-28 | 1997-08-01 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation |
| GB9600272D0 (en) * | 1996-01-06 | 1996-03-06 | Univ Nottingham | Polymers |
| US5704908A (en) * | 1996-10-10 | 1998-01-06 | Genetronics, Inc. | Electroporation and iontophoresis catheter with porous balloon |
| GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
| US6048551A (en) * | 1997-03-27 | 2000-04-11 | Hilfinger; John M. | Microsphere encapsulation of gene transfer vectors |
| FR2766706B1 (fr) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics Sa | Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation |
| US6040925A (en) | 1997-12-12 | 2000-03-21 | Hewlett-Packard Company | Radial and pruned radial interpolation |
| US6383811B2 (en) * | 1997-12-30 | 2002-05-07 | Mirus Corporation | Polyampholytes for delivering polyions to a cell |
| CA2337652C (en) * | 1998-07-13 | 2013-03-26 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US7396919B1 (en) * | 1998-07-17 | 2008-07-08 | Mirus Bio Corporation | Charge reversal of polyion complexes |
| US5945290A (en) * | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
| FR2786098B1 (fr) * | 1998-11-20 | 2003-05-30 | Flamel Tech Sa | Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication |
| WO2000078791A2 (en) | 1999-06-17 | 2000-12-28 | Universiteit Gent | FUNCTIONAL POLY-α-AMINOACID DERIVATIVES USEFUL FOR THE MODIFICATION OF BIOLOGICALLY ACTIVE MATERIALS AND THEIR APPLICATION |
| WO2000078358A2 (en) | 1999-06-18 | 2000-12-28 | The Collaborative Group, Ltd. | Hyaluronic acid microspheres for sustained gene transfer |
| EP1209971A4 (en) | 1999-08-20 | 2004-04-14 | Mirus Corp | POLYION COMPLEX LOAD INVERSION |
| AU2001241958A1 (en) * | 2000-03-03 | 2001-09-17 | Valentis, Inc. | Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| CA2423093C (en) * | 2000-09-25 | 2013-09-17 | Valentis, Inc. | Improved system for regulation of transgene expression |
-
2001
- 2001-03-02 AU AU2001245427A patent/AU2001245427A1/en not_active Abandoned
- 2001-03-02 EP EP01918339A patent/EP1259265B1/en not_active Expired - Lifetime
- 2001-03-02 CA CA2401327A patent/CA2401327C/en not_active Expired - Lifetime
- 2001-03-02 JP JP2001564801A patent/JP4987205B2/ja not_active Expired - Lifetime
- 2001-03-02 BR BR0108962-5A patent/BR0108962A/pt not_active IP Right Cessation
- 2001-03-02 DK DK01918339.1T patent/DK1259265T3/da active
- 2001-03-02 WO PCT/US2001/006953 patent/WO2001066149A2/en not_active Ceased
- 2001-03-02 AT AT01918339T patent/ATE511400T1/de not_active IP Right Cessation
-
2002
- 2002-09-03 US US10/234,406 patent/US7173116B2/en not_active Expired - Lifetime
-
2006
- 2006-11-20 US US11/561,847 patent/US7491537B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003525912A5 (enExample) | ||
| EP1259265B1 (en) | Nucleic acid formulations for gene delivery | |
| KR101092547B1 (ko) | 하나 이상의 활성 성분의 지속성 배출을 위한 약학적 제제및 이의 치료적 용도 | |
| JP6444310B2 (ja) | モノクローナル抗体の安定化方法 | |
| Su et al. | Chiral polypeptide nanoparticles as nanoadjuvants of nanovaccines for efficient cancer prevention and therapy | |
| KR102432434B1 (ko) | Rna 투여용 제형 | |
| RU2010133905A (ru) | Монолитные альгинатные имплантаты in situ | |
| US7297676B2 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
| US20070218142A1 (en) | Pharmaceutical Formulations For The Prolonged Release Of Interleukins And Their Therapeutic Applications | |
| AU755126B2 (en) | Stable gene preparations | |
| CN116236565A (zh) | 适合于肌注给药的核酸-脂质纳米颗粒、制剂及其应用 | |
| KR20060111594A (ko) | 인터페론의 지속성 배출을 위한 약학적 제제 및 이의치료적 용도 | |
| CN118320110A (zh) | 一种白血病用共载肿瘤抗原和免疫佐剂的囊泡纳米疫苗及其制备与应用 | |
| JP5798628B2 (ja) | ウシ顆粒球コロニー刺激因子のための製剤およびその変異体 | |
| Chiang et al. | Contribution of poly (amino acids) to advances in pharmaceutical biotechnology | |
| RU2797147C2 (ru) | Рецептура для введения рнк | |
| US20240189414A1 (en) | Engineered heartland virus mrna vaccine | |
| WO2008150196A1 (ru) | Кровезаменитель с функцией переноса кислорода | |
| Kainthan | Commercialized nanomedicines until to date | |
| JPH01149717A (ja) | 直腸内投与用医薬組成物 | |
| WO2024131862A1 (zh) | 一种rsv疫苗及其制备方法与应用 | |
| CN116807973A (zh) | 一种可调控pKa的纳米分子伴侣体系及其制备和应用 | |
| ES2364812T3 (es) | Formulaciones de ácido nucleico para su liberación génica. | |
| JP2015086140A (ja) | 耐熱性を有するタンパク質水性懸濁剤 | |
| JP2015086142A (ja) | 凝集抑制性を有するタンパク質水性懸濁剤 |